LONDON--(BUSINESS WIRE)--Though the global fight against malaria is seeing greater success than it did in the late 90s and early 2000s, malaria is still a potent worldwide health threat. According to the WHO, in 2015 nearly half the world’s population was at risk of malaria, with ongoing malaria transmission in 91 countries and regions. This continuing threat must be combatted against with the use of anti-malaria drugs and treatments.
Every year, nearly 300 million individuals globally are affected by malaria, and more than a million people die from the disease. According to Infiniti Research, the prominence of this disease is driving the market for anti-malaria drugs and similar medications to grow at a rate of almost 7% by 2020. The latest study from Infiniti Research analyzes the changing demand-supply landscape of antimalarial treatment market across targeted tropical countries.
A new scientific breakthrough announced this week will bring the world one step closer to the widespread availability of a malaria vaccine, and can aid in the development of other biologic and non-biologic anti-malaria drugs. Researchers at the Australian National University (ANU) have discovered a molecule which can kill microbes that infect the liver, including malaria, and have developed an experimental vaccine that could prevent against malaria and similar diseases. In the researchers’ initial trials, 64% of vaccinated participants (nine out of fourteen people) showed no signs of infection after first exposure. Six of these participants were then exposed to a different strain of malaria; of these six, only one person become infected and was promptly treated. This is substantial protection after just six months of development and testing, and is a hopeful indicator that the vaccine can become 100% effective after further development and research.
A malaria vaccine would bring much needed relief to areas greatly affected by the disease, including many in Africa and Asia. This vaccine has the potential to eradicate malaria worldwide, increasing quality of life and life expectancy in hard-hit regions.
To understand the demand for this vaccine and other anti-malaria drugs in different markets and regions around the world, market intelligence is essential. Vendors must have a clear picture of the incidence of malaria in different countries, as well as how accessible and available healthcare and medication is to people in different regions.
Infiniti Research recently worked with a leading global healthcare company with core business in pharmaceuticals, vaccines, and generics to understand the future potential for antimalarial drugs in countries like Nigeria, Indonesia, India, and Brazil. The numerous insights provided by the market intelligence solutions experts at Infiniti Research helped client resolve strategic and tactical issues by transforming marketing and sales strategies.
Have questions about this study? Request more information on this report
Related Healthcare Industry Research Studies:
About Infiniti Research
Established in 2003, Infiniti Research is a leading market intelligence company providing smart solutions to address your business challenges. Infiniti Research studies markets in more than 100 countries to help analyze competitive activity, see beyond market disruptions, and develop intelligent business strategies.
With 13 years of experience and offices across three continents, Infiniti Research has been instrumental in providing a complete range of competitive intelligence, strategy, and research services for over 550 companies across the globe.